Beyond the cholesterol-lowering properties of statins, studies in animal models have shown that statins reduce the levels of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, and modulate small guanine triphosphate-binding proteins, the proliferator-activated receptor α, and paraoxonase 1, thereby exerting anti-inflammatory and anti-fibrotic effects on MASLD [35]. The gene discussed is PON1; the disease is metabolic dysfunction-associated steatotic liver disease.